Trial Profile
Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Effects of Intra-Erythrocyte Dexamethasone Sodium Phosphate on Neurological Symptoms in Patients With Ataxia Telangiectasia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Jan 2024
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary)
- Indications Ataxia telangiectasia
- Focus Registrational; Therapeutic Use
- Acronyms ATTEST; ATTeST
- Sponsors EryDel
- 24 Jul 2023 According to a Quince Therapeutics media release, the company is Pursuing European regulatory activities related to potential MAA submission of EryDex based on this trial.
- 26 Apr 2022 Primary endpoint (Modified International Cooperative Ataxia Rating Scale (mICARS) has not been met according to the results presented at the 74th Annual Meeting of the American Academy of Neurology 2022
- 26 Apr 2022 Results assessing efficacy and safety of monthly infusions of intra-erythrocyte dexamethasone phosphate (EDS) in patients with A-T presented at the 74th Annual Meeting of the American Academy of Neurology 2022